Logo for Orphazyme

Orphazyme Investor Relations Material

Latest events

Logo for Orphazyme

H1 2021

Logo for Orphazyme

H1 2023

12 Sep, 2023
Logo for Orphazyme

H2 2022

25 Apr, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Orphazyme

Access all reports
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company's lead drug candidate is epoprostenol sodium and its analogues, Phase III ready lipidic compounds, which are being developed as an innovative treatment option targeting the underlying cause of these diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.